Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
604 Results for "
SCO2 mutations
" in MedChemExpress (MCE) Product Catalog:
Products (604)
604 Results for "SCO2 mutations" in MCE Product Catalog:
Cat. No.: HY-161233A
BTX-6654 formate is a SOS1 PROTAC degrader. BTX-6654 formate induces ubiquitination and degradation of SOS1 via the proteasomal pathway by bridging SOS1 with the E3 ligase CRBN to form a ternary complex, thereby blocking KRAS activation and downregulating the MAPK signaling pathway (pERK/pS6), and ultimately inhibiting tumor growth. BTX-6654 formate can be used in research on various cancers driven by KRAS mutations .
Cat. No.: HY-164492
CAS No.: 1455031-68-1
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and Raf dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or RAF dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation [2].
Cat. No.: HY-170845
CAS No.: 2379671-78-8
Target:
Research Areas:
MU1409 is an inhibitor of MRE11 nuclease with an IC50 of 12.1 μM. Additionally, MU1409 also inhibits FEN1 and EXO1, with IC50 values of 24.2 and 176.4 μM, respectively. MU1409 affects DNA repair in cells, preventing the degradation of stalled replication forks in BRCA2-deficient cells, making it a promising candidate for research on BRCA2 mutation-induced cancers .
Cat. No.: HY-174856
PROTAC HBeAg degrader-1 is a HBeAg-targeting PROTAC degrader that recruits VHL. PROTAC HBeAg degrader-1 degrades HBeAg and reduces HBcAg levels in a largely VHL-independent manner, and inhibits secreted HBeAg in a concentration-dependent manner, with particularly stronger inhibitory activity against the HAP-resistant (HBVT109I mutation) strain . PROTAC HBeAg degrader-1 can be used in studies related to hepatitis B virus infection .
Cat. No.: HY-175281
CAS No.: 2933135-82-9
SJ11646 is a LCK PROTAC degrader with a DC50 value of 0.00838 pM against LCK. SJ11646 recruits CRBN and LCK to form a ternary complex, inducing cereblon-mediated proteasomal degradation of LCK. SJ11646 induces cytotoxicity in T-ALL cells, but such cytotoxicity is reduced in cells harboring the LCK T316I mutation. SJ11646 can be used in studies related to T-cell acute lymphoblastic leukemia [2].
Cat. No.: HY-176250
KRAS-IN-43 (Compound 9) is a pan-KRAS inhibitor with IC50 values of 0.15 μM, 0.14 μM, and 0.47 μM against KRAS G12V, KRAS G12C and wild-type KRAS, respectively. KRAS-IN-43 disrupts the interaction between KRAS and cRAF, and inhibits ERK phosphorylation. KRAS-IN-43 is promising for research of KRAS mutation-related cancers (such as pancreatic cancer, colorectal cancer, and lung cancer) .
Cat. No.: HY-176523
CAS No.: 3018057-89-8
KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective KRAS G12D mutant inhibitor. KRAS G12D inhibitor 29 blocks downstream signaling pathways mediated by KRAS G12D, suppressing tumor cell proliferation. KRAS G12D inhibitor 29 is promising for research of KRAS G12D mutation-related cancers (such as pancreatic cancer, lung cancer, colorectal cancer) .
Cat. No.: HY-177895
CAS No.: 3031413-24-5
IAM1363 is a selective, irreversible, and blood-brain barrier-permeable HER2 inhibitor . IAM1363 targets wild-type HER2 and oncogenic HER2 mutants (including exon 20 mutations), with no off-target EGFR inhibitory activity. IAM1363 can be used to study HER2-driven solid tumors, including colorectal cancer, non-small cell lung cancer, bladder cancer, and breast cancer [2].
Cat. No.: HY-178108
Research Areas:
Anti-MRSA agent 35 (Compound 6b) is an anti-MRSA agent. Anti-MRSA agent 35 significantly inhibits MRSA biofilm formation, suppresses penicillin-binding protein (PBP2a) expression and induces mecA virulence gene mutation. Anti-MRSA agent 35 has potent bactericidal and fungicidal activities with MIC50s of 7.8-31.25 μg/mL for gram positive bacteria, gram-negative bacteria and Fungi. .
Cat. No.: HY-178824
CAS No.: 1454651-67-2
EGFR-IN-180 (Compound L15) is an EGFR inhibitor. EGFR-IN-180 shows inhibitory activity against EFGR and EGFR harboring the L858R/T790M/C797S triple drug-resistant mutation, with IC50 values of 80.96 nM and 16.43 nM, reapectively. EGFR-IN-180 can be used for the study of non-small cell lung cancer (NSCLC) .
Cat. No.: HY-186283
CAS No.: 2719667-13-5
GNE-0749 is an orally active pan-RAF inhibitor with a Ki value of 0.061 nM against CRAF. GNE-0749 inhibits RAF dimer signaling via a DFG-out/αC-helix-in binding mode, prevents paradoxical activation of the MAPK pathway, and suppresses downstream MEK/ERK/RSK signal transduction. GNE-0749 can be used in studies related to KRAS G12C mutation-driven cancers [2] .
Cat. No.: HY-189268
Target:
Research Areas:
RET-IN-36 is an orally active RET kinase inhibitor. RET-IN-36 overcomes gatekeeper and solvent front resistance mutations and inhibits the proliferation of cells expressing RET G810C and RET V804M mutants by suppressing RET phosphorylation and SHC downstream signaling. RET-IN-36 can be used for research on RET-mutant cancers, medullary thyroid cancer, papillary thyroid cancer, and non-small cell lung cancer [2].
Cat. No.: HY-P991572
CAS No.: 1399724-72-1
Cat. No.: HY-P991922
Research Areas:
AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [ 177Lu] radiolabeled AKIR001, namely [ 177Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma .
Cat. No.: HY-P99674
CAS No.: 2364496-42-2
Synonyms: GEN3009
Target:
Research Areas:
Ivicentamab (GEN3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research .
Cat. No.: HY-W095672A
CAS No.: 2097518-76-6
Target:
Research Areas:
(2R,7aS)-2-Fluorotetrahydro-1H-pyrrolizine-7a(5H)-methanol is a drug intermediate for synthesis of various active compounds. (2R,7aS)-2-Fluorotetrahydro-1H-pyrrolizine-7a(5H)-methanol is a core structural framework of the compounds targeting KRAS G12D mutation.
Cat. No.: HY-W752587
CAS No.: 349553-98-6
Synonyms: (±)-Mevalonolactone-d4; Mevalolactone-d4
Cat. No.: HY-178061
CAS No.: 2598870-24-5
APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
Cat. No.: HY-117622
CAS No.: 1388894-17-4
Target:
Research Areas:
ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets
the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models .
Cat. No.: HY-131603B
CAS No.: 2736455-56-2
Synonyms: 3TCTP TEA
Research Areas:
Lamivudine triphosphate (3TCTP) TEA is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate TEA inhibits the reverse transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate TEA is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate TEA can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
